1. HBW Insight
  2. >>Health

Naloxone Still On US House Appropriators’ Radar, But OTC Access Remains Off Screen

FDA FY2022 Budget Report Comments On Switches, Acetaminophen Labeling, Homeopathics

 
• By Malcolm Spicer

Committee report again includes item concerning FDA’s work on expanding access to opioid antagonist naloxone. It still doesn’t acknowledge agency’s interest in making drug available OTC in a nasal inhaler, but emphasizes access for pregnant and postpartum women.

House appropriators’ changes in their comments on the US Food and Drug Administration’s work on expanding access to the opioid overdose remedy naloxone miss the point about making it available nonprescription as the agency has emphasized.

The Appropriation Committee’s report published with legislation for the FDA’s fiscal year 2022 funding along with budgets for the Department...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

More from Policy & Regulation